

**Supplementary Table 4.** Comparison of clinical characteristics between the good responders and the poor responders in the add-on and switch group

Characteristic	Add-on			Switch		
	Good responder (n=119)	Poor responder (n=88)	P value	Good responder (n=52)	Poor responder (n=151)	P value
Age, yr	58.8±11.5	61.9±9.9	0.047	48.0±13.4	59.5±12.4	0.453
Female sex	67 (56.3)	59 (67.0)	0.150	30 (57.7)	80 (53.0)	0.629
BMI, kg/m <sup>2</sup>	27.2±4.4	26.7±3.7	0.452	28.7±6.1	27.2±4.9	0.149
Duration of diabetes, yr	11.4±8.3	13.9±8.9	0.034	10.6±7.9	11.7±7.6	0.387
Subtype of SGLT2 inhibitors, dapagliflozin:empagliflozin	102:17	77:11	0.838	35:17	113:38	0.366
Hypertension	89 (74.8)	62 (70.5)	0.529	32 (61.5)	114 (75.5)	0.073
Dyslipidemia	101 (84.9)	74 (84.1)	0.878	44 (84.6)	129 (85.4)	0.886
HbA1c, %	8.8±1.1	8.3±1.0	0.002	8.8±1.6	8.2±1.1	0.012
FPG, mg/dL	169.5±43.7	158.4±40.0	0.063	147.1±34.4	148.8±43.5	0.803
Fasting C-peptide, ng/mL	2.6±1.7	2.5±1.1	0.728	2.5±1.3	2.3±1.7	0.825
Fasting insulin, mIU/L	17.8±10.4	12.9±3.0	0.207	NA	NA	NA
HOMA-β	73.9±49.1	50.7±16.2	0.216	NA	NA	NA
HOMA-IR	7.0±3.8	5.0±1.1	0.149	NA	NA	NA
eGFR, mL/min/1.73 m <sup>2</sup>	93.3±25.3	89.7±19.1	0.265	92.8±20.6	89.7±23.5	0.411
Insulin therapy	36 (30.3)	42 (47.7)	0.014	18 (34.6)	58 (38.4)	0.740

Values are presented as mean ± standard deviation or number (%).

BMI, body mass index; SGLT2, sodium-glucose cotransporter-2; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; NA, not applicable; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate.